SalvGlandDx – a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets
Diagnosis of salivary gland neoplasms is often challenging due to their high morphological diversity and overlaps. Several recurrent molecular alterations have been described recently, which can serve as powerful diagnostic tools and potential therapeutic targets (e.g. NTRK or RET fusions). However,...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-05-01
|
Series: | Neoplasia: An International Journal for Oncology Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S147655862100018X |
id |
doaj-07d220f8e060469d809549e7e9a329cb |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sandra N. Freiberger Muriel Brada Christine Fritz Sylvia Höller Alexander Vogetseder Milo Horcic Michel Bihl Michal Michal Martin Lanzer Martin Wartenberg Urs Borner Peter K. Bode Martina A. Broglie Tamara Rordorf Grégoire B. Morand Niels J. Rupp |
spellingShingle |
Sandra N. Freiberger Muriel Brada Christine Fritz Sylvia Höller Alexander Vogetseder Milo Horcic Michel Bihl Michal Michal Martin Lanzer Martin Wartenberg Urs Borner Peter K. Bode Martina A. Broglie Tamara Rordorf Grégoire B. Morand Niels J. Rupp SalvGlandDx – a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets Neoplasia: An International Journal for Oncology Research Salivary gland neoplasm Biopsy FNA Molecular Comprehensive Testing |
author_facet |
Sandra N. Freiberger Muriel Brada Christine Fritz Sylvia Höller Alexander Vogetseder Milo Horcic Michel Bihl Michal Michal Martin Lanzer Martin Wartenberg Urs Borner Peter K. Bode Martina A. Broglie Tamara Rordorf Grégoire B. Morand Niels J. Rupp |
author_sort |
Sandra N. Freiberger |
title |
SalvGlandDx – a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets |
title_short |
SalvGlandDx – a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets |
title_full |
SalvGlandDx – a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets |
title_fullStr |
SalvGlandDx – a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets |
title_full_unstemmed |
SalvGlandDx – a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets |
title_sort |
salvglanddx – a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets |
publisher |
Elsevier |
series |
Neoplasia: An International Journal for Oncology Research |
issn |
1476-5586 |
publishDate |
2021-05-01 |
description |
Diagnosis of salivary gland neoplasms is often challenging due to their high morphological diversity and overlaps. Several recurrent molecular alterations have been described recently, which can serve as powerful diagnostic tools and potential therapeutic targets (e.g. NTRK or RET fusions). However, current sequential molecular testing can be expensive and time consuming. In order to facilitate the diagnosis of salivary gland neoplasms, we designed an all-in-one RNA-based next generation sequencing panel suitable for the detection of mutations, fusions and gene expression levels (including NR4A3) of 27 genes involved in salivary gland neoplasms. Here we present the validation of the “SalvGlandDx” panel on FFPE histological specimen including fine needle aspiration (FNA) cell block material, against the standard methods currently used at our institution. In a second part we describe selected unique cases in which the SalvGlandDx panel allowed proper diagnosis and new insights into special molecular characteristics of selected salivary gland tumors. We characterize a unique salivary gland adenocarcinoma harboring a ZCCHC7-NTRK2 fusion, a highly uncommon spindle cell and pseudoangiomatoid adenoid-cystic carcinoma with MYBL1-NFIB fusion, and a purely oncocytic mucoepidermoid carcinoma, whereas diagnosis could be made by detection of a CRTC3-MAML2 rearrangement on the cell block specimen of the FNA. Further, a rare case of a SS18-ZBTB7A rearranged low-grade adenocarcinoma previously described as potential spectrum of microsecretory adenocarcinoma, is reported. In addition, features of six cases within the spectrum of polymorphous adenocarcinoma / cribriform adenocarcinoma of salivary gland including PRKD1 p.E710D mutations and novel fusions involving PRKAR2A-PRKD1, SNX9-PRKD1 and ATL2-PRKD3, are described. |
topic |
Salivary gland neoplasm Biopsy FNA Molecular Comprehensive Testing |
url |
http://www.sciencedirect.com/science/article/pii/S147655862100018X |
work_keys_str_mv |
AT sandranfreiberger salvglanddxacomprehensivesalivaryglandneoplasmspecificnextgenerationsequencingpaneltofacilitatediagnosisandidentifytherapeutictargets AT murielbrada salvglanddxacomprehensivesalivaryglandneoplasmspecificnextgenerationsequencingpaneltofacilitatediagnosisandidentifytherapeutictargets AT christinefritz salvglanddxacomprehensivesalivaryglandneoplasmspecificnextgenerationsequencingpaneltofacilitatediagnosisandidentifytherapeutictargets AT sylviaholler salvglanddxacomprehensivesalivaryglandneoplasmspecificnextgenerationsequencingpaneltofacilitatediagnosisandidentifytherapeutictargets AT alexandervogetseder salvglanddxacomprehensivesalivaryglandneoplasmspecificnextgenerationsequencingpaneltofacilitatediagnosisandidentifytherapeutictargets AT milohorcic salvglanddxacomprehensivesalivaryglandneoplasmspecificnextgenerationsequencingpaneltofacilitatediagnosisandidentifytherapeutictargets AT michelbihl salvglanddxacomprehensivesalivaryglandneoplasmspecificnextgenerationsequencingpaneltofacilitatediagnosisandidentifytherapeutictargets AT michalmichal salvglanddxacomprehensivesalivaryglandneoplasmspecificnextgenerationsequencingpaneltofacilitatediagnosisandidentifytherapeutictargets AT martinlanzer salvglanddxacomprehensivesalivaryglandneoplasmspecificnextgenerationsequencingpaneltofacilitatediagnosisandidentifytherapeutictargets AT martinwartenberg salvglanddxacomprehensivesalivaryglandneoplasmspecificnextgenerationsequencingpaneltofacilitatediagnosisandidentifytherapeutictargets AT ursborner salvglanddxacomprehensivesalivaryglandneoplasmspecificnextgenerationsequencingpaneltofacilitatediagnosisandidentifytherapeutictargets AT peterkbode salvglanddxacomprehensivesalivaryglandneoplasmspecificnextgenerationsequencingpaneltofacilitatediagnosisandidentifytherapeutictargets AT martinaabroglie salvglanddxacomprehensivesalivaryglandneoplasmspecificnextgenerationsequencingpaneltofacilitatediagnosisandidentifytherapeutictargets AT tamararordorf salvglanddxacomprehensivesalivaryglandneoplasmspecificnextgenerationsequencingpaneltofacilitatediagnosisandidentifytherapeutictargets AT gregoirebmorand salvglanddxacomprehensivesalivaryglandneoplasmspecificnextgenerationsequencingpaneltofacilitatediagnosisandidentifytherapeutictargets AT nielsjrupp salvglanddxacomprehensivesalivaryglandneoplasmspecificnextgenerationsequencingpaneltofacilitatediagnosisandidentifytherapeutictargets |
_version_ |
1721453449999024128 |
spelling |
doaj-07d220f8e060469d809549e7e9a329cb2021-05-10T07:02:45ZengElsevierNeoplasia: An International Journal for Oncology Research1476-55862021-05-01235473487SalvGlandDx – a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targetsSandra N. Freiberger0Muriel Brada1Christine Fritz2Sylvia Höller3Alexander Vogetseder4Milo Horcic5Michel Bihl6Michal Michal7Martin Lanzer8Martin Wartenberg9Urs Borner10Peter K. Bode11Martina A. Broglie12Tamara Rordorf13Grégoire B. Morand14Niels J. Rupp15Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland; University of Zurich, Zurich, SwitzerlandDepartment of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland; University of Zurich, Zurich, SwitzerlandDepartment of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland; University of Zurich, Zurich, SwitzerlandDepartment of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland; University of Zurich, Zurich, SwitzerlandDepartment of Pathology, Cantonal Hospital of Lucerne, Lucerne, SwitzerlandInstitute for Histological and Cytological Diagnostics AG, Aarau, SwitzerlandDepartment of Pathology and Medical Genetics, University Hospital Basel, Basel, SwitzerlandSikl's Department of Pathology, Medical Faculty in Pilsen, Charles University in Prague, Pilsen, Czech Republic; Bioptical Laboratory, Pilsen, Czech RepublicDepartment of Oral and Maxillofacial Surgery, University Hospital Zurich, Zurich, Switzerland; University of Zurich, Zurich, SwitzerlandInstitute of Pathology, University of Bern, Bern, SwitzerlandDepartment of Otorhinolaryngology, Head and Neck Surgery, Inselspital, Bern University Hospital and University of Bern, Bern, SwitzerlandDepartment of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland; University of Zurich, Zurich, SwitzerlandDepartment of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich, Zurich, Switzerland; University of Zurich, Zurich, SwitzerlandDepartment of Medical Oncology, University Hospital Zurich, Zurich, Switzerland; University of Zurich, Zurich, SwitzerlandDepartment of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich, Zurich, Switzerland; Department of Otolaryngology-Head and Neck Surgery, Sir Mortimer B. Davis- Jewish General Hospital, McGill University, Montreal, Quebec, Canada; University of Zurich, Zurich, SwitzerlandDepartment of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland; University of Zurich, Zurich, Switzerland; Corresponding author: Niels J. Rupp, MD, Department of Pathology and Molecular Pathology, University Hospital Zurich, Schmelzbergstrasse 12, 8091 Zurich, Switzerland, Tel. +41 44 255 50 91, Fax. +41 44 255 44 40Diagnosis of salivary gland neoplasms is often challenging due to their high morphological diversity and overlaps. Several recurrent molecular alterations have been described recently, which can serve as powerful diagnostic tools and potential therapeutic targets (e.g. NTRK or RET fusions). However, current sequential molecular testing can be expensive and time consuming. In order to facilitate the diagnosis of salivary gland neoplasms, we designed an all-in-one RNA-based next generation sequencing panel suitable for the detection of mutations, fusions and gene expression levels (including NR4A3) of 27 genes involved in salivary gland neoplasms. Here we present the validation of the “SalvGlandDx” panel on FFPE histological specimen including fine needle aspiration (FNA) cell block material, against the standard methods currently used at our institution. In a second part we describe selected unique cases in which the SalvGlandDx panel allowed proper diagnosis and new insights into special molecular characteristics of selected salivary gland tumors. We characterize a unique salivary gland adenocarcinoma harboring a ZCCHC7-NTRK2 fusion, a highly uncommon spindle cell and pseudoangiomatoid adenoid-cystic carcinoma with MYBL1-NFIB fusion, and a purely oncocytic mucoepidermoid carcinoma, whereas diagnosis could be made by detection of a CRTC3-MAML2 rearrangement on the cell block specimen of the FNA. Further, a rare case of a SS18-ZBTB7A rearranged low-grade adenocarcinoma previously described as potential spectrum of microsecretory adenocarcinoma, is reported. In addition, features of six cases within the spectrum of polymorphous adenocarcinoma / cribriform adenocarcinoma of salivary gland including PRKD1 p.E710D mutations and novel fusions involving PRKAR2A-PRKD1, SNX9-PRKD1 and ATL2-PRKD3, are described.http://www.sciencedirect.com/science/article/pii/S147655862100018XSalivary gland neoplasmBiopsyFNAMolecularComprehensiveTesting |